$BMY News Market rookie Five Prime's shares surge on deal

New Post Public Reply Private Reply Replies (0) Message Board

Apr 3, 2014 at 11:12 AM

$BMY News

Market rookie Five Prime's shares surge on deal with Bristol-Myers 12:01 p.m. March 17, 2014 - Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike 5:19 p.m. March 4, 2014 - Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment 5:01 p.m. March 4, 2014 - Russ Britt
Billionaire Stan Druckenmiller's recent moves 12:50 p.m. Feb. 24, 2014 - Insider Monkey
Feds, pharma rivals team up on Alzheimer's 3:32 p.m. Feb. 6, 2014 - Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug 12:16 p.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 6:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 4:50 p.m. Jan. 24, 2014 - Sue Chang
U.S. stock futures trim losses ahead of market open 9:57 a.m. Jan. 24, 2014 - Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch 6:38 a.m. Jan. 24, 2014 - Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo 3:44 a.m. Jan. 22, 2014 - MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings 9:01 a.m. Jan. 19, 2014 - Wallace Witkowski
America's best and most generous 401(k)s 3:30 p.m. Jan. 15, 2014 - Anne Tergesen
Merck initiates melanoma filing with FDA 12:45 p.m. Jan. 13, 2014 - Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain 2:02 p.m. Jan. 8, 2014 - Russ Britt
Not all pharmaceuticals are created equal 1:40 p.m. Dec. 26, 2013 - The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper 1:06 p.m. Dec. 19, 2013 - Sara Sjolin
European stocks rally on Fed taper, rate views 1:00 p.m. Dec. 19, 2013 - Sara Sjolin
AstraZeneca to buy Bristol-Myers diabetes-JV stake 4:25 a.m. Dec. 19, 2013 - MarketWatch.com
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 12:12 p.m. Dec. 10, 2013 - Russ Britt

Tradable Biotech Stocks Events For the Second Quarter 9:00 a.m. Today - TheStreet.com
Why Bristol-Myers Squibb is a Top 25 Dividend Giant (BMY) 5:35 a.m. Today - InvestorPlace.com
China still bright for Big Pharma 11:30 a.m. April 2, 2014 - Seeking Alpha
Glaxo Suffers Another Setback 5:26 a.m. April 2, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Pushing The Drugs Industry Lower 1:03 p.m. April 1, 2014 - TheStreet.com
Sales Soar for Pricey Hepatitis Drug Sovaldi 8:16 p.m. March 31, 2014 - The Wall Street Journal Interactive Edition
Which Pharmas Can Keep Up Dividend-Buybacks? 3:02 p.m. March 31, 2014 - Seeking Alpha
Amgen Stock Gets Bump Up On Cholesterol Drug Data 12:59 p.m. March 31, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: MA, SLB, BMY 12:18 p.m. March 31, 2014 - TheStreet.com
Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN) 12:03 p.m. March 31, 2014 - TheStreet.com
Don't Give Up On Momentum 8:36 p.m. March 28, 2014 - Seeking Alpha
Gilead Sovaldi Scrips Falter As Biotechs Keep Falling 3:42 p.m. March 28, 2014 - Investors Business Daily
Government agency plans to shake down Big Pharma 1:54 p.m. March 28, 2014 - Seeking Alpha
A Look Back At Big Pharma Stocks 4:58 p.m. March 27, 2014 - Seeking Alpha
Bristol-Myers Still Lags in Hepatitis C 8:19 a.m. March 27, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Beware the Vacuum 8:03 p.m. March 26, 2014 - TheStreet.com
3 Stocks Reiterated As A Buy: MSFT, BMY, CAT 12:14 p.m. March 26, 2014 - TheStreet.com
J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now 8:15 a.m. March 26, 2014 - 247WallSt.com
Novo Nordisk Upgraded to 'Buy' 11:43 a.m. March 24, 2014 - FOXBusiness
Drug Firms Focus on Advanced Melanoma 8:11 p.m. March 23, 2014 - The Wall Street Journal Interactive Edition

Theravance Appoints Kevin Kwok, Head of Talent Acquisition and Strategy 4:05 p.m. April 1, 2014 - Marketwire
Bristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29 9:00 a.m. April 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Executive Maclean Becomes Precision Health Economics' Chief Operating Officer 10:22 a.m. March 31, 2014 - PR Newswire - PRF
INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors 1:50 a.m. March 31, 2014 - GlobeNewswire
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool 4:51 p.m. March 26, 2014 - PR Newswire - PRF
Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit 12:11 p.m. March 26, 2014 - PR Newswire - PRF
Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results 4:30 p.m. March 25, 2014 - GlobeNewswire
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer 8:00 a.m. March 25, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Genotypes at The International Liver CongressTM 5:39 a.m. March 24, 2014 - BusinessWire - BZX
FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Trace One Names Mark Martini as Vice President of North America to Lead Sales and Customer Development 9:01 a.m. March 20, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 8:15 a.m. March 19, 2014 - GlobeNewswire
Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly 8:00 a.m. March 19, 2014 - PR Newswire - PRF
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways 6:59 a.m. March 17, 2014 - BusinessWire - BZX
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways 6:59 a.m. March 17, 2014 - GlobeNewswire
U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 1:00 p.m. March 14, 2014 - BusinessWire - BZX
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE 8:00 a.m. March 14, 2014 - PR Newswire - PRF
Pharma-Biotech Industry Helps Drive $14.4 Billion Industrial Project Activity in Massachusetts, an Industrial Info News Alert 6:30 a.m. March 10, 2014 - Marketwire
Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented 12:30 p.m. March 4, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

First Horizon's $25M Bet: New Center Transforms Houston

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

ACME's AI Innovation Shakes Up Filmmaking Scene

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

Citigroup, Scotia Aid TSTT in $500M Note Offering

Kicking off with a banger that’s got financial water coolers buzzing, Greenberg Traurig just pulled a rabbit out of the hat helping Citigroup and Scotia Capital orchestrate a chunky near $500 million dual-currency notes deal for Telecommunications Services of Trinidad and Tobago Limited (TSTT). Now, this isn’t your run-of-the-mill market maneuver. We're seeing a...

Toys"R"Us Rolls Out 160 U.S. Stores, NYC Celebration

Rebuilding the Toy Empire After a rough few years, Toys"R"Us is clawing its way back into the hearts—and wallets—of American shoppers. With 160+ new standalone stores popping up like mushrooms after rain, these guys aren't just playing games. This is a strategic move to reestablish their presence in the retail landscape just before the holiday shopping frenzy kicks...

Terra Kaffe's Big Win with Oprah's Endorsement

Terra Kaffe Hits the Jackpot with Oprah Sometimes, destiny has a way of handing out golden tickets, and for Terra Kaffe, receiving a nod from Oprah Winfrey's revered list of Favorite Things for 2026 is nothing short of that. I mean, you can't underestimate the pull Mrs. O has. Her endorsement isn’t just another celebrity pat-on-the-back, it’s a megaphone blaring...

CVRx Faces Legal Storm: Investors Grapple with Fallout

CVRx in the Crosshairs: Legal and Operational Woes There's a storm brewing over at CVRx, Inc. (NASDAQ: CVRX), and it's pulling investors down a hell of a financial rabbit hole. You might think you're in the clear with a company like CVRx that boasts approved devices, but think again. Recent revelations have shown that even those with FDA stamps aren't immune to the...

YYForce Expands in UAE with Key Hospitality Wins

Unveiling YYForce's Middle East Strategy Smack in the middle of an aggressive Middle Eastern expansion, YYForce (NASDAQ: YFOR) is making waves with some new headline-grabbing contracts in the UAE. This ain't just a side hustle—it's big time. They're planting their flag across the luxury hospitality sector like they're going for a moon landing. The recent announcement...

Immunic, Inc. Steams Ahead: Phase 3 Trials Hinge on MS Data

A Pivotal Moment for Immunic We’re staring down a critical December for Immunic, Inc. as they trot out top-line data for their Phase 3 ENSURE trials aimed at relapsing multiple sclerosis (MS). Now, I’m all ears wondering if those trials can hold water — success could morph them from a tinkering biotech into a commercial giant. For market vultures like us,...

CR&R Workers Join Teamsters, Fight for Fair Conditions

Waste Workers Push Back Against Corporate Pressure The Southern California sun isn't the only thing heating up these days; the waste workers at CR&R Environmental Services have cranked up the heat by voting to join Teamsters Local 396. It's like Groundhog Day in the world of labor rights—same story, different locale, workers banding together for a fair shot. A Stand...

Kentucky Power's Bold Plan to Boost Local Economy

Electricity, Economy, and Execution Kentucky Power just laid out plans that could massively swing the pendulum for eastern Kentucky's economic prospects. They've put filings on the table for the Kentucky Public Service Commission that, if approved, promise big economic benefits. We're talking about a potential infusion of $500 million through fixed-rate offsets and an...